FDA Approves First Therapy for Rare Disease that Causes Low Phosphate Blood Levels, Bone Softening
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized …
Read More